Core Viewpoint - WuXi AppTec (02268) experienced a significant stock price increase, reaching a new high of HKD 75.8, with a current rise of 4.97% to HKD 73.9, and a trading volume of HKD 201 million [1] Group 1: Company Announcement - WuXi AppTec announced a subscription agreement with WuXi Biologics on September 3, involving the issuance of 24.13 million new shares, representing approximately 1.96% of the company's total issued share capital as of the last practicable date [1] - Following the completion of the subscription, WuXi Biologics' ownership will increase from 48.81% to 50.74%, while the ownership of other public shareholders will decrease from 28.76% to 28.21% [1] Group 2: Financial Details - The net proceeds from the subscription are approximately HKD 1.414 billion, which will be used to expand the group's service capabilities and production capacity [1] - About 90% of the proceeds will be allocated to the expansion of production capacity for bioconjugated drugs and related products, while approximately 10% will be used for general working capital needs [1]

Core Viewpoint - WuXi AppTec (02268) saw its stock price rise over 7%, reaching a new high of HKD 75.8, following the announcement of a subscription agreement with WuXi Biologics [1] Group 1: Stock Performance - The stock price increased by 4.97% to HKD 73.9, with a trading volume of HKD 201 million [1] Group 2: Subscription Agreement - WuXi AppTec announced a subscription agreement signed with WuXi Biologics on September 3, involving the issuance of 24.13 million new shares, representing approximately 1.96% of the company's issued share capital as of the last practicable date [1] - Following the completion of the subscription, WuXi Biologics' ownership will increase from 48.81% to 50.74%, while the public shareholders' stake will decrease from 28.76% to 28.21% [1] Group 3: Use of Proceeds - The net proceeds from the subscription are approximately HKD 1.414 billion, with about 90% allocated for expanding the production capacity of bioconjugates and related products, and around 10% for general operational funding needs [1]

Core Viewpoint - WuXi AppTec (02268) experienced a significant stock price increase, reaching a new high of HKD 75.8, with a current rise of 4.97% to HKD 73.9, and a trading volume of HKD 201 million [1] Group 1: Company Announcement - WuXi AppTec announced a subscription agreement with WuXi Biologics on September 3, involving the issuance of 24.13 million new shares, representing approximately 1.96% of the company's total issued share capital as of the last practicable date [1] - Following the completion of the subscription, WuXi Biologics' ownership will increase from 48.81% to 50.74%, while the public shareholders' stake will decrease from 28.76% to 28.21% [1] Group 2: Financial Details - The net proceeds from the subscription are approximately HKD 1.414 billion, which will be used to expand the group's service capabilities and production capacity [1] - About 90% of the proceeds will be allocated to the expansion of production capacity for bioconjugated drugs and related products, while approximately 10% will be used for general working capital needs [1]

Core Viewpoint - The National Healthcare Security Administration has announced the 11th batch of centralized drug procurement, set to open bids on October 21 in Shanghai, covering 55 varieties and 162 specifications of drugs, including key areas like antiviral and innovative kidney disease treatments [1] Group 1: Procurement Details - The procurement will include various dosage forms such as oral immediate-release forms, inhalants, and topical patches [1] - The principle of "anti-involution" is emphasized, indicating that the procurement is not aimed at price wars but rather at balancing drug prices and values [1] Group 2: Industry Impact - The procurement aims to stabilize clinical practices, ensure quality, prevent collusion, and promote innovation, laying a foundation for high-quality development in the pharmaceutical industry [1] - Companies with strong R&D capabilities and unique products are expected to gain larger market shares through price-volume strategies, leading to increased demand [1] Group 3: Market Reaction - The announcement has positively impacted the market, with the Hang Seng Pharmaceutical ETF (159892) rising over 2%, and stocks like WuXi AppTec gaining over 5%, leading the pharmaceutical sector [1]

（股份代號：2268） WUXI XDC CAYMAN INC. 藥明合聯生物技術有限公司* （於開曼群島註冊成立的有限公司） 與 本 代 表 委 任 表 格 有 關 的 股 份 數 目 （附 註1） 將 於2025年10月9日（星 期 四）舉 行 的 股 東 特 別 大 會 代 表 委 任 表 格 本 人╱我 們 （附 註2） 地 址 為 為 本 人╱我 們 的 受 委 代 表，出 席 本 公 司 謹 訂 於2025年10月9日（星 期 四）上 午 十 時 正 假 座 中 國 江 蘇 省 無 錫 市 新 吳 區 新 華 路5 號 亞 朵 酒 店 舉 行 的 股 東 特 別 大 會（「股 東 特 別 大 會」）（及 其 任 何 續 會），以 代 表 本 人╱我 們 按 下 列 指 示 行 事 及 表 決。 請 在 適 當 欄 內 填 上「 」號，以 表 示 閣 下 的 投 票 意 願 （附 註4） 。 | | | 普 通 決 議 案 贊 成 反 對 | | --- | --- | --- | | 1. | 動 議： | | | | (a) | | | | | 批准、確認及追認本公司（作為發行人）與藥明生物技術 ...

股 東 特 別 大 會 通 知 茲 通 知 藥 明 合 聯 生 物 技 術 有 限 公 司*（「本 公 司」）謹 訂 於2025年10月9日（星 期 四） 上 午 十 時 正 假 座 中 國 江 蘇 省 無 錫 市 新 吳 區 新 華 路5號 亞 朵 酒 店 舉 行 股 東 特 別 大 會（「大 會」），藉 以 考 慮 及 酌 情 通 過（不 論 有 否 修 訂）以 下 決 議 案 為 本 公 司 普 通 決 議 案。除 非 另 有 界 定，本 通 知 所 用 詞 彙 與 本 公 司 日 期 為2025年9月22日 的 通 函 所 界 定 者 具 有 相 同 涵 義。 普 通 決 議 案 「動 議： – 1 – 1. (i) 批准、確認及追認本公司（作為發行人）與藥明生物技術有限公司（「認購人」） （作為認購人）所訂立日期為2025年9月3日的認購協議（「認購協議」，註有「A」 字 樣 之 副 本 已 提 呈 股 東 特 別 大 會，且 經 股 東 特 別 大 會 主 席 簽 署 以 資 識 別）（據 此，本 公 司 已 有 條 件 同 意 向 認 購 人 發 行 及 配 發 而 認 購 人 已 有 條 件 ...

此 乃 要 件 請 即 處 理 閣 下 對 本 通 函 任 何 方 面 或 應 採 取 的 行 動 如 有 任 何 疑 問，應 諮 詢 股 票 經 紀 或 其 他 註 冊 證 券 交 易 商、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣 下 如 已 出 售 或 轉 讓 名 下 所 有 藥 明 合 聯 生 物 技 術 有 限 公 司*的 股 份，應 立 即 將 本 通 函 連 同 隨 附 的 代 表 委 任 表 格 送 交 買 主 或 承 讓 人、或 經 手 買 賣 或 轉 讓 的 銀 行、股 票 經 紀 或 其 他 代 理 人，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 通 函 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 WUXI XDC CA ...

Core Insights - The Chinese innovative pharmaceutical industry is experiencing significant growth as companies expand overseas through various strategies such as licensing, establishing overseas bases, and forming new companies [1][10] - A notable challenge faced by Chinese pharmaceutical companies is the shortage of talent, particularly when transitioning to international multi-center clinical trials [1][9] Group 1: Market Expansion - By 2025, Chinese innovative pharmaceutical companies are expected to maintain their momentum in international markets [1] - Over 40% of business development deals with upfront payments exceeding $50 million are now attributed to Chinese biotech firms, a significant increase from less than 5% four years ago [3] - The historical shift in global pricing power for Chinese innovative drugs reflects a transition from weakness to strength [3] Group 2: Case Studies - The case of Hutchison China MediTech illustrates the difficulties faced during global expansion, highlighting the need for collaboration with established pharmaceutical companies to navigate complex global operations [4] - The approval of the drug fruquintinib in the U.S. in late 2023, after a partnership with Takeda Pharmaceuticals, underscores the importance of strategic alliances in overcoming initial setbacks [4] Group 3: ADC Development - Antibody-drug conjugates (ADCs) have emerged as a key area for Chinese innovative drug development, with companies like WuXi AppTec and Kelun-Biotech securing significant deals with international firms [4] - The combination of chemical advantages and innovative approaches in ADC development positions Chinese companies favorably in the global market [4] Group 4: Talent Acquisition and Challenges - Talent shortages remain a critical challenge for Chinese pharmaceutical companies as they expand internationally, necessitating a focus on both recruitment and training [9] - WuXi AppTec's establishment of its first overseas factory in Singapore reflects a strategic choice based on execution, management, and government support [8] - The company emphasizes the importance of local talent availability and has implemented a strategy of combining local hiring with the relocation of domestic employees to build a balanced workforce [8][9] Group 5: Future Outlook - The next few years are expected to see an increase in the number of ADCs launched in China, with companies advised to align closely with the needs and development directions of multinational corporations [5] - The evolution of Chinese pharmaceutical companies into the "outbound 2.0 era" signifies a shift towards deeper integration into the global market and competition with top multinational firms [10]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI XDC CAYMAN INC. （於開曼群島註冊成立的有限公司） 藥 明 合 聯 生 物 技 術 有 限 公 司* （股份代號：2268） 本公司預期將於2025年10月9 日（ 星期四 ）召開股東特別大會，以供獨立股東考慮 及酌情批准認購協議及其項下擬進行的交易以及特別授權。鑒於預計舉行的股東 特別大會及為釐定股東出席股東特別大會並於會上投票的權利，本公司將於2025 年10 月6 日（ 星期一 ）至2025 年10月 9 日（ 星期四 ）止（ 包 括首尾兩 天 ）暫停辦 理股份 過戶登記手續，在此期間概不會辦理任何股份過戶登記。 為符合資格出席股東特別大會並於會上投票，所有過戶文件連同有關股票必須在 不遲於2025年10月3日（ 星期五 ）下午四時三十分送達本公司的香港股份過戶登記 處 香 港 中 央 證券 登 記 有 限 ...

Group 1 - As of September 19, 93 stocks reached their 52-week highs, with Huake Intelligent Investment (01140), Xincheng Power (01148), and Huashang Energy (00206) leading the increase rates at 22.30%, 20.00%, and 17.65% respectively [1] - The closing prices for the top three stocks that reached new highs are Huake Intelligent Investment at 0.170, Xincheng Power at 0.300, and Huashang Energy at 0.305 [1] - Other notable stocks that reached new highs include Handa Fu Holdings (01348) with a high rate of 16.89% and Meijiehui Holdings (01389) at 13.75% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Shanga Holdings (00412) experiencing the largest decline at -34.98%, followed by Huaying Construction (01582) at -21.47% [3] - The closing price for Shanga Holdings is 3.360, while Huaying Construction closed at 0.360 [3] - Other stocks with significant declines include China Information Technology Equity (08568) at -17.74% and Tai Hing Properties (00277) at -11.90% [3]